S&P Futures
3,933.00 +16.75 (+0.43%) Dow Futures
31,581.00 +94.00 (+0.30%) Nasdaq Futures
12,211.50 +71.00 (+0.58%) Russell 2000 Futures
1,770.10 +8.40 (+0.48%) Crude Oil
107.83 +0.21 (+0.20%) Gold
1,840.30 +10.00 (+0.55%)
PharmaCyte Biotech, Inc. (PMCB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.0900 |
| Open | 2.1100 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 800 |
| Day's Range | 2.1001 - 2.1872 |
| 52 Week Range | 1.7900 - 22.1650 |
| Volume | |
| Avg. Volume | 463,345 |
| Market Cap | 45.172M |
| Beta (5Y Monthly) | -0.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PMCB
Related Research
- PharmaCyte Biotech, Inc.HALO: Raising target price to $60.00HALOZYME THERAPEUTICS INC has an Investment Rating of BUY; a target price of $60.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat5 days agoArgus Research
- PR Newswire
IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING
Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 6.1% of the outstanding common stock of the Company, today announced that it has nominated a slate of seven (7) highly qualified director candidates for election to the PharmaCyte Board of Directors at the Company's upcoming 2022 annual meeting of stockholders. Iroquois als
- Business Wire
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
LAS VEGAS, June 15, 2022--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to the second letter issued by Iroquois Capital (Iroquois) on June 9, 2022:
- Business Wire
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
LAS VEGAS, June 13, 2022--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will represent PharmaCyte at the 2022 BIO International Convention (BIO) being held at the San Diego Convention Center in San Diego, California, June 13-16.
